CB3304 (Noscapine)
CB3304 is an orally active alkaloid derived from opium. Preclinical studies have shown that CB3304 is a microtubule targeting agent that alters microtubule dynamics (see Figure 1 below), blocks mitosis, and causes apoptosis. Preclinical antitumor activity has been demonstrated in a number of tumor types including preclinical models of lymphoma, breast cancer, bladder cancer, melanoma and glioblastoma. CB3304 has also shown the ability to inhibit the proliferation of both paclitaxel sensitive and paclitaxel resistant human ovarian carcinoma cell lines.
|
Figure 1: Gallery of video frames, 10 seconds apart, demonstrating the effect of CB3304 (noscapine) on microtubule dynamics (fixed pixel positions are marked with arrowheads). In control cells, microtubules alternated between phases of growth and shortening; therefore, the position of their plus ends changes significantly over time. In cells treated with CB3304, microtubule dynamics were suppressed; therefore, the position of their plus ends was unaltered. (Landen, Cancer Research, 2002)
|
A Phase I/II trial of CB3304 in patients with hematological malignancies is currently ongoing at the University of Southern California/Norris Comprehensive Cancer Center.
|
|
|
